Grown Rogue International Inc (GRUSF) Fair Value & Analysis
Healthcare · US · Market cap $107M
Grown Rogue International Inc
GRUSF · US
Fair value as of: Jul 16, 2026
From 14 valuation models · updated 25 days ago
Share price −6.3% over the past month.
Below-average quality, and screening another 74% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.1445). The favourable scenario is already priced in.
- Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range $0.0400 – $0.8300 · fair‑value band $0.0850 – $0.1445 · the $0.4300 price screens above the $0.1105 fair value. Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Grown Rogue International Inc (GRUSF) currently trades at $0.4300, while our model-based Fair Value estimate is $0.1105, implying the stock looks roughly 74.3% overvalued today. The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Grown Rogue International Inc generated revenue of $34.4M at a net margin of -4.6%. Revenue grew 28.0% year over year. It earns a return on equity of 1.3%. Net debt stands at $1.2M. Fundamentals as of Jul 16, 2026
Our scenario range runs from $0.0850 (bear case) to $0.1445 (bull case); at $0.4300, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 17% below its 52-week high and 59% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -74%, GRUSF screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Growth Earnings ($0.3200) versus Economic Profit ($0.0400). Highest evidence: ROIC Compounder (72).
Notify me when GRUSF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 55
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Grown Rogue International Inc., through its subsidiaries, engages in cultivation, manufacture, possession, sale, and distribution of marijuana in the United States. It offers flower and flower pre-rolls, as well as flower-based products. The company also produces recreational marijuana and distributes it to dispensaries. Grown Rogue International Inc.
Full company description
Grown Rogue International Inc., through its subsidiaries, engages in cultivation, manufacture, possession, sale, and distribution of marijuana in the United States. It offers flower and flower pre-rolls, as well as flower-based products. The company also produces recreational marijuana and distributes it to dispensaries. Grown Rogue International Inc. is headquartered in Medford, Oregon.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Grown Rogue International Inc reported revenue of $32.4M in FY2025 versus $9.4M in FY2021, a compound +36.4%/yr. Reported net income was $1.7M in FY2025.
GRUSF screens 74% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Grown Rogue International Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Grown Rogue International Inc (GRUSF) overvalued or undervalued?
What is the fair value of GRUSF?
What is the quality score of GRUSF?
What is the revenue of Grown Rogue International Inc (GRUSF)?
What is the net profit margin of GRUSF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Grown Rogue International Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.